Business
Reeves’ ‘mansion tax’ makes ‘no sense’, former IFS director warns
Rachel Reeves’s plans to levy a “mansion tax” on high-value properties make no sense and could cause the Treasury to lose money, one of Britain’s leading economists has warned.
Paul Johnson, the former director of the Institute for Fiscal Studies (IFS), told The Independent he was “staggered” at reports that the Treasury is considering such a move, saying it could “block up the entire housing market”.
His intervention came as mortgage brokers and financial planners rounded on the chancellor after reports that she is considering hitting the owners of expensive properties when they sell to plug a £40bn hole in the public purse.
The mooted plans would mean higher-rate taxpayers paying 24 per cent of any gain in the value of their home, while basic rate taxpayers would be hit with an 18 per cent levy. Currently, capital gains tax is not paid on the sale of primary residences.
The threshold is still under consideration, sources told The Times, but a £1.5m starting point would hit around 120,000 homeowners who are higher-rate taxpayers. with capital gains tax bills of £199,973.
Mr Johnson called for a major overhaul of housing taxation as a whole, warning that levying capital gains tax on high-value properties at the same time as stamp duty would mean “no one would ever sell their properties”.
“I think there are all sorts of practical problems with it. It would gum up the housing market at the top end hopelessly. So I think, personally, it’s a non-runner. I think it would be very hard to design in a way that would raise significant money, and indeed, it could lose the Treasury money. Because, you know, you could lose the money you’re currently getting in stamp duty.
“I just can’t believe that they’re considering it. I’m staggered that they’re flying this flag. It, to me, makes no sense.”
Calling for an overhaul of housing taxation, Mr Johnson said council tax was “far too low on expensive properties” while stamp duty is a “disaster area”. But he said that “talking about [levying] capital gains tax when you’ve still got stamp duty would clearly be hopeless. You need to think about these in conjunction with one another. It’s just not sensible in any world to be talking about these things individually.”
Mr Johnson said the stagnation in the property market would be made even worse if the Conservatives pledged to reverse any such policy. “That would guarantee that nobody would move. People would hope that someone else would win the next election and wait to sell. So there’s a huge practical problem there.”
Property experts also warned that such a plan would stall housing sales and add to the exodus of the super-rich from the UK.
Financial adviser Scott Gallacher, a director at Rowley Turton wealth management, said a level of £1.5m would prevent most older homeowners, particularly those who bought properties in the 1980s and 90s, from selling houses.
He added that this would “kill off the upper end of the property market” and be difficult to implement. Mr Gallacher said: “It would be insane if it creates a cliff edge in that properties over £1.5m are subject to capital gains tax on the entire gain, as properties sold at £1.49m would incur no CGT, whereas £1.5m might be a six-figure bill. If it’s only on gains above £1.5m, then the CGT raised would be minimal, as potentially you’d be exempting six or even seven-figure gains.”
He added: “Homeowners, especially older ones, who perhaps bought their houses in the 1970s or 1980s, would be daft to sell and incur a huge CGT liability. Instead, they would be incentivised to hold on to the home until they die and pay no CGT.”
Simon Gerrard, chairman of Martyn Gerrard Estate Agents, warned that a mansion tax plan would leave families who bought homes in London more than a decade ago facing “eye-watering” tax bills. “Meanwhile, those who are actually wealthy know how to bypass these moves and won’t pay it,” he said.
He told The Independent: “After the deadline passes, people will simply not sell their homes. The property market above the threshold will die until Labour are voted out and the policy is repealed under a more sensible government.”
Laith Khalaf, head of investment analysis at AJ Bell, said the tax-free nature of primary residences was “deeply embedded in the psyche of homeowners”.
He warned: “A mansion tax set at high level would naturally cause people to worry it was just the thin end of the wedge, and the next time the government needs a bit of money they could just lower the threshold.
“It would also be an impediment to mobility in the housing market, as those with properties which might fall foul of the tax would be inclined to sit on them for longer, leaving a log jam in the housing ladder below them.”
And critics warned the tax change would add to the reported exodus of super-rich individuals fleeing Britain. Stephen Perkins, managing director of Yellow Brick Mortgages, said: “I can see a lot of families in London being caught with this higher tax bill, and it may push more wealthy tax contributors to exodus the UK, which is already a problem following the Chancellor’s last budget.”
A Treasury spokesman said: “The best way to strengthen public finances is by growing the economy, which is our focus. Changes to tax-and-spend policy are not the only ways of doing this, as seen with our planning reforms, which are expected to grow the economy by £6.8bn and cut borrowing by £3.4bn
“We are committed to keeping taxes for working people as low as possible, which is why at last autumn’s Budget we protected working people’s payslips and kept our promise not to raise the basic, higher or additional rates of income tax, employee national insurance, or VAT.”
Business
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025.
Mike Blake | Reuters
Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the Trump administration to make the medicine more accessible.
The announcement also comes weeks after chief rival Novo Nordisk unveiled additional discounts on the cash prices of its obesity and diabetes drugs.
Starting Monday, cash-paying patients with a valid prescription can get the starting dose of Zepbound vials for as low as $299 per month on LillyDirect, down from a previous price of $349 per month. They can also access the next dose, 5 milligrams, for $399 per month and all other doses for $449 per month, down from $499 per month across those sizes.
Zepbound carries a list price of roughly $1,086 per month. That price point, and spotty insurance coverage for weight loss drugs in the U.S., have been significant barriers to access for some patients.
Eli Lilly’s announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to get and afford. The agreements will cut the prices the government pays for the drugs, introduce Medicare coverage of obesity drugs for the first time for certain patients and offer discounted medicines on the government’s new direct-to-consumer website launching in January, TrumpRx.
But Eli Lilly’s deal with Trump centers around lowering the prices of a different form of Zepbound – a multi-dose pen – after it wins Food and Drug Administration approval.
That means Eli Lilly’s Monday announcement around cutting prices on the existing single-dose vials could allow more patients to get discounted treatments more quickly.
“We will keep working to provide more options — expanding choices for delivery devices and creating new pathways for access — so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities, in a statement.
Eli Lilly’s stock, which has climbed more than 36% this year, fell nearly 2% on Monday. Its meteoric rise due to the success of Zepbound and its diabetes injection Mounjaro vaulted it to becoming the first health-care company to hit a $1 trillion market value last month. Though cutting prices means lower revenue per medication sold, Eli Lilly’s sales — and shares — have continued to soar through past pricing announcements as demand balloons.
With single-dose vials, patients need to use a syringe and needle to draw up the medicine and inject it into themselves. Eli Lilly first introduced that form of Zepbound in August 2024.
It’s unclear how many patients are currently using single-dose vials of Zepbound. But Eli Lilly previously said that direct-to-consumer sales now account for more than a third of new prescriptions of Zepbound.
Novo Nordisk earlier this month lowered the price of its obesity drug Wegovy and diabetes treatment Ozempic for existing cash-paying patients to $349 per month from $499 per month. That excludes the highest dose of Ozempic.
The company also launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment.
Business
OGRA Announces LPG Price Increase for December – SUCH TV
The Oil and Gas Regulatory Authority (OGRA) has approved a fresh increase in the price of liquefied petroleum gas (LPG), raising the cost for both domestic consumers and commercial users.
According to the notification issued, the LPG price has been increased by Rs7.39 per kilogram, setting the new rate at Rs209 per kg for December. As a result, the price of a domestic LPG cylinder has risen by Rs87.21, bringing the new price to Rs2,466.10.
In November, the price of LPG stood at Rs201 per kg, while the domestic cylinder was priced at Rs2,378.89.
The latest price hike is expected to put additional pressure on households already grappling with rising living costs nationwide.
Business
Taxable Value Of Goods Surges 15% In Sep-Oct As GST Cuts Boost Consumption
New Delhi: The taxable value of all supplies under GST surged by a robust 15 per cent during September-October this year, compared to the same period in 2024 due to sharp increase in consumption triggered by the tax rate cuts on goods across sectors that kicked in from September 22, according to official sources.
The growth in the same two-month period last year was 8.6 per cent. “This surge in taxable value during ‘Bachat Utsav’ demonstrates strong consumption uplift, stimulated by reduced rates and improved compliance behaviour,” a senior official said.
He pointed out that the growth has especially been strong in sectors where rate rationalisation was implemented, such as FMCG, pharma goods, food products, automobiles, medical devices and textiles. In these sectors, the taxable value of supplies has seen significantly higher growth, confirming that lower GST rates translated directly into higher consumer spending.
“It vindicates our strategy that reducing rates on essentials and mass-use sectors would create demand-side buoyancy — a Laffer Curve–type demand uplift,” he explained.These trends confirm that GST next-gen reforms have not disrupted revenue stability, and that consumption-side buoyancy has begun to translate into higher taxable value in key sectors.
This growth is in value terms which means that since GST rates were lower, the growth in volume terms will be even higher. It is clearly visible that while the Next Gen Reforms resulted in significant Bachat — increased consumption, industry has been very proactive in passing on the GST savings to the final consumers and ensuring that there is no supply side deficiency.
As GDP private consumption data will be released much later, GST taxable value serves as the most reliable real-time proxy for consumption, and the current numbers clearly indicate sustained demand expansion, the official added.
-
Sports1 week agoWATCH: Ronaldo scores spectacular bicycle kick
-
Entertainment1 week agoWelcome to Derry’ episode 5 delivers shocking twist
-
Politics1 week agoWashington and Kyiv Stress Any Peace Deal Must Fully Respect Ukraine’s Sovereignty
-
Business1 week agoKey economic data and trends that will shape Rachel Reeves’ Budget
-
Politics1 week ago53,000 Sikhs vote in Ottawa Khalistan Referendum amid Carney-Modi trade talks scrutiny
-
Tech6 days agoWake Up—the Best Black Friday Mattress Sales Are Here
-
Tech1 day agoGet Your Steps In From Your Home Office With This Walking Pad—On Sale This Week
-
Fashion1 week agoCanada’s Lululemon unveils team Canada kit for Milano Cortina 2026
